TY - CHAP
T1 - Experimental schizophrenia models in rodents established with inflammatory agents and cytokines
AU - Nawa, Hiroyuki
AU - Yamada, Kiyofumi
PY - 2012
Y1 - 2012
N2 - Immune inflammatory processes in prenatal and perinatal stages are suggested to play crucial roles in the vulnerability to schizophrenia. Based upon this immune inflammatory hypothesis for schizophrenia, we have established animal models for this illness by subcutaneously administering cytokines or proinflammatory agents to rodent neonates. These models exhibit various schizophrenia-like behavioral abnormalities after puberty, most of which are sensitive to various antipsychotics. The experimental procedures are all simple and easily utilized by researchers unfamiliar with these models. The behavioral changes are reproducible and remarkable but do not accompany learning deficits. The molecular and cellular targets of these agents have also been investigated and partially characterized, such as the cortical GABAergic system, midbrain dopaminergic system and hippocampal glutamate system. In this chapter, we introduce the details of the procedure and discuss the potential application of these animal models to drug development for schizophrenia.
AB - Immune inflammatory processes in prenatal and perinatal stages are suggested to play crucial roles in the vulnerability to schizophrenia. Based upon this immune inflammatory hypothesis for schizophrenia, we have established animal models for this illness by subcutaneously administering cytokines or proinflammatory agents to rodent neonates. These models exhibit various schizophrenia-like behavioral abnormalities after puberty, most of which are sensitive to various antipsychotics. The experimental procedures are all simple and easily utilized by researchers unfamiliar with these models. The behavioral changes are reproducible and remarkable but do not accompany learning deficits. The molecular and cellular targets of these agents have also been investigated and partially characterized, such as the cortical GABAergic system, midbrain dopaminergic system and hippocampal glutamate system. In this chapter, we introduce the details of the procedure and discuss the potential application of these animal models to drug development for schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=84856351556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856351556&partnerID=8YFLogxK
U2 - 10.1007/978-1-61779-458-2_28
DO - 10.1007/978-1-61779-458-2_28
M3 - Chapter
C2 - 22231831
AN - SCOPUS:84856351556
SN - 9781617794575
T3 - Methods in Molecular Biology
SP - 445
EP - 451
BT - Psychiatric Disorders
A2 - Kobeissy, Firas
ER -